Selank Peptide Shows Potent Antiviral Activity Against Influenza Virus
Background
Seasonal influenza virus infections remain a significant global health concern, necessitating the continuous development of new antiviral agents. Current treatments often face challenges like drug resistance and side effects. Selank, a synthetic peptide derived from the endogenous human immunomodulatory peptide tuftsin, is known for its anxiolytic and nootropic effects. This study aimed to evaluate the direct antiviral and immunomodulatory properties of Selank against the influenza A/Aichi 2/68 (H3N2) strain.
Results
The study revealed a pronounced antiviral effect of Selank in both in vitro and in vivo settings. In cell cultures, Selank demonstrated its highest efficiency when administered preventively, completely suppressing viral reproduction when added 24 hours prior to inoculation. In vivo, the preventive administration of Selank also led to the highest survival rates among the infected laboratory animals compared to control groups. Furthermore, Selank treatment significantly induced the gene expression of interferon-alpha (IFN-alpha), a crucial antiviral cytokine, without affecting the expression levels of interleukin-4 (IL-4), interleukin-10 (IL-10), or tumor necrosis factor-alpha (TNF-alpha). This suggests a specific immunomodulatory pathway. The most significant finding was that Selank, when used preventively, completely suppressed influenza virus reproduction in cell culture and resulted in the highest survival rates in infected animals.
Why It Matters
These findings highlight Selank's potential as a novel antiviral agent, particularly for influenza prevention. The ability of Selank to modulate the immune response by selectively upregulating IFN-alpha suggests a targeted mechanism of action, potentially offering a new strategy for combating viral infections. Given that Selank is synthesized based on an endogenous peptide and reportedly has no negative effects, it presents a promising candidate for further development into a therapeutic or prophylactic agent against influenza. Future research should focus on dose-response studies, efficacy against other influenza strains, and progression to human clinical trials (e.g., Phase I/II) to confirm its safety and effectiveness.